The Impact of the Oncotype DX® Breast Cancer Assay on Treatment Decisions in a Canadian Population of Patients With Estrogen Receptor- Positive Early Breast Cancer With 1-3 Positive Lymph Nodes
The main goal of this study is to characterize whether the results of the Oncotype DX® assay
affect the physician's treatment recommendations for the adjuvant treatment of women with
ER-positive (ER+), early breast cancer (EBC) with 1-3 positive lymph nodes who are potential
candidates for chemotherapy, but for whom the benefits of chemotherapy may be uncertain.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society